Loading clinical trials...

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC | Clinical Trials | Clareo Health

TERMINATEDPHASE3

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (IressaTM) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy

NCT00234468•AstraZeneca

View on ClinicalTrials.gov

Summary

The aim of the study if to determine if Iressa can prolong the period of time without any disease worsening (Time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or without radiotherapy or chemotherapy and radiotherapy

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically Confirmed Non Small Cell Lung Cancer.
•Locally advanced disease previously treated with combined therapy (chemotherapy and surgery with or without radiotherapy, or chemotherapy and radiotherapy).
•Chemotherapy with regimens containing cisplatin or carboplatin is mandatory
•Response to combined therapy

Exclusion Criteria

•No previous treatment with ZD1839 or any other EGFR-targeted therapy
•No progressive disease after combined therapy for locally advanced NSCLC
•No presence of metastatic disease
•No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
•Any unresolved chronic toxicity from previous anticancer therapy.

Locations (32)

Research Site

Avellino, Italy

Research Site

Bergamo, Italy

Research Site

Bologna, Italy

Research Site

Cagliari, Italy

Research Site

Campobasso, Italy

Research Site

Catania, Italy

Research Site

Catanzaro, Italy

Research Site

Chieti, Italy

Research Site

Cosenza, Italy

Research Site

Della Fratte, Italy

Key Dates

Start Date

January 1, 2004

Completion Date

August 1, 2007

Last Updated

May 20, 2011

Enrollment

490

ESTIMATED participants

Conditions

Non Small Cell Lung Carcinoma

Interventions

Iressa (Gefitinib)

DRUG

Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.

NCT00759382

Non Small Cell Lung Carcinoma

View study

TERMINATEDPHASE2

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

NCT00592007

Non Small Cell Lung Carcinoma

View study

COMPLETEDPHASE1

Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 20, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions